BCL2 and osteosarcoma: It is possible that regorafenib’s ability to sensitize osteosarcoma cells to S63845-mediated death in vitro may reflect its ability to alter the balance between pro- and anti-apoptotic members of the BCL-2 family (Supplementary Fig. 1).